CONNECT: Extra Post-discharge Phone Support to Reinforce After-Visit Summaries

Communication Outreach for Navigation and Needs-based Care Transitions (CONNECT): A Pilot Randomized Controlled Trial

Not applicable Interventional Boston Medical Center · NCT07032818

This pilot tests whether adding a detailed, language-concordant post-discharge phone call helps patients who prefer Spanish, Haitian Creole, Portuguese, Cape Verdean, or Vietnamese understand their after-visit summary and avoid problems after leaving the hospital.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment60 (estimated)
Ages18 Years and up
SexAll
SponsorBoston Medical Center Academic / other
Locations1 site (Boston, Massachusetts)
Trial IDNCT07032818 on ClinicalTrials.gov

What this trial studies

This pilot randomized controlled trial at Boston Medical Center uses a 2:1 allocation to compare standard discharge education with an enhanced intervention that adds a detailed post-discharge phone call to reinforce the After Visit Summary (AVS). The control group receives a nurse review of the AVS and an automated English follow-up call, while the intervention group receives those plus an additional phone call in the patient’s preferred language to review instructions. Eligible participants are medicine inpatients being discharged home who have a registered preference for Spanish, Haitian Creole, Portuguese, Cape Verdean, or Vietnamese; patients with active infection or suicide precautions, cognitive impairment, or a previously observed discharge are excluded. Outcomes will focus on comprehension of discharge instructions, post-discharge problems including medication errors, and 30-day readmissions.

Who should consider this trial

Good fit: Ideal candidates are medicine patients at Boston Medical Center being discharged to home who have a registered preference for Spanish, Haitian Creole, Portuguese, Cape Verdean, or Vietnamese.

Not a fit: Patients who do not prefer the listed languages, who are discharged to a facility rather than home, or who have active cognitive impairment, delirium, or infection/safety precautions are unlikely to be eligible or to benefit.

Why it matters

Potential benefit: If successful, this approach could improve patients' understanding of discharge instructions and reduce medication errors and short-term readmissions among people with non-English language preferences.

How similar studies have performed: Prior research of post-discharge phone calls and reinforced discharge education has shown mixed but sometimes positive effects on understanding and readmissions, while adaptations specifically for patients with non-English language preference are less well studied.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Registered language in Epic (written or spoken) is Spanish, Haitian Creole, Portuguese, Cape Verdean, or Vietnamese
* Admitted to medicine team at Boston Medical Center (BMC)
* Being discharged home (to the community)

Exclusion Criteria:

* On airborne infections precautions at time of recruitment
* On C diff precautions at time of recruitment
* On suicide precautions at time of recruitment
* Nurse report of participant displaying cognitive impairment, ongoing delirium, or aggression
* Discharge observed during a prior admission

Where this trial is running

Boston, Massachusetts

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Communication ResearchDischarge instructionsNon-English language preferenceAdapting hospital discharge
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.